Trials / Withdrawn
WithdrawnNCT00584090
Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of South Florida · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to measure the efficacy of solifenacin succinate (VESIcare) on treating urinary incontinence in Parkinson's disease patients. The secondary objective of this study is to examine the effect of solifenacin succinate (VESIcare) on symptoms of PD and the patient's quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Solifenacin Succinate (VESIcare) | 5 - 10 mg po qd for 1 month |
| DRUG | Placebo | Placebo equivalent of 5-10 mg po qd for 1 month |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2011-04-01
- First posted
- 2008-01-02
- Last updated
- 2012-12-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00584090. Inclusion in this directory is not an endorsement.